Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 171

Sort by

Sort Order Select

Journal Articles

B-ALL with intrachromosomal amplification of chromosome 21 in a carrier of the Robertsonian translocation rob(14;21)c

Qingsong Gao, Christine J. Harrison

Blood (2024) 143 (25): 2672.

https://doi.org/10.1182/blood.2024023923

Published: 2024

Journal Articles

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

Blood (2023) 142 (Supplement 1): 1063.

https://doi.org/10.1182/blood-2023-178798

Published: 2023

Journal Articles

A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma

Andy Tang, Kihyun Kim, Fiona Chen, Zoe K McQuilten, Peter Mollee, Rajeev Rajagopal, Hang Quach, Phoebe Joy Ho, Simon J. Harrison, Andrew Spencer, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2023-178192

Published: 2023

Journal Articles

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

Blood (2023) 142 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2023-178778

Published: 2023

Journal Articles

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 6939.

https://doi.org/10.1182/blood-2023-178806

Published: 2023

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J. Harrison, Nieves Lopez-Muñoz

Blood (2023) 142 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2023-182141

Published: 2023

Journal Articles

Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody

Iryna Dekhtiarenko, Iva Lelios, Wolfgang Jacob, Meike Schneider, Martin Weisser, Carmelo Carlo-Stella, Salomon Manier, Simon J. Harrison, Rakesh Popat, Anna Caroline Hasselbalch Riley, Ann-Marie E. Bröske

Blood (2023) 142 (Supplement 1): 1948.

https://doi.org/10.1182/blood-2023-177669

Published: 2023

Journal Articles

The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21

Blood (2023) 142 (8): 711–723.

https://doi.org/10.1182/blood.2022019094

Published: 2023

Includes: Supplemental data

Journal Articles

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodriguez Otero, Simon J Harrison, Chihunt Wong, Grant R. Goodman, Rin Nakamura, Voleak Choeurng, James Cooper, Maria-Victoria Mateos

Blood (2022) 140 (Supplement 1): 1363–1365.

https://doi.org/10.1182/blood-2022-159381

Published: 2022

Journal Articles

Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia

Blood (2022) 140 (Supplement 1): 6356–6357.

https://doi.org/10.1182/blood-2022-165985

Published: 2022

Journal Articles

Whole Genome Sequencing for Detection of Prognostically Relevant Genetic Abnormalities in Paediatric Acute Myeloid Leukaemia

Claire Schwab, Ruth E Cranston, Emily Winterman, Jelena Jovanovic, Zoya Kingsbury, Terena James, Martina Mijuskovic, Enes Tuc, Richard Dillon, Brenda Gibson, Mark Ross, Christine J. Harrison

Blood (2022) 140 (Supplement 1): 3204–3205.

https://doi.org/10.1182/blood-2022-163184

Published: 2022

Journal Articles

Infectious Complications of Bispecific Antibody Therapy in Patients with Multiple Myeloma

Beatrice Z Sim, Anthony Longhitano, Jeremy Er, Simon J Harrison, Monica Slavin, Benjamin W Teh

Blood (2022) 140 (Supplement 1): 4384–4385.

https://doi.org/10.1182/blood-2022-167834

Published: 2022

Journal Articles

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Blood (2022) 140 (Supplement 1): 4415–4417.

https://doi.org/10.1182/blood-2022-157547

Published: 2022

Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 7261–7263.

https://doi.org/10.1182/blood-2022-163809

Published: 2022

Journal Articles

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Blood (2022) 140 (Supplement 1): 397–399.

https://doi.org/10.1182/blood-2022-157988

Published: 2022

Journal Articles

Treatment Outcomes of Childhood Picalm:MLLT10 + Acute Leukemias: An International Retrospective Study

Blood (2022) 140 (Supplement 1): 3403–3404.

https://doi.org/10.1182/blood-2022-156731

Published: 2022

Journal Articles

The Efficacy of Same Day Plerixafor Dosing on CD34+ Haematopoietic Stem Cell Collection: A Single Centre Australian Experience

Kaitlyn M Wiltshire, David Routledge, Trish Joyce, Simon J Harrison

Blood (2022) 140 (Supplement 1): 12805.

https://doi.org/10.1182/blood-2022-171173

Published: 2022

Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Blood (2022) 140 (Supplement 1): 10137–10139.

https://doi.org/10.1182/blood-2022-158146

Published: 2022

Journal Articles

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

David Sharon, Fengjiao Dunbar, Paul Jung, Xifeng Wang, Xiaotong Li, Christine Mantis, Orlando F. Bueno, Cyrille Touzeau, Philippe Moreau, Simon J Harrison, Luciano J. Costa, Jonathan L. Kaufman, Nizar J. Bahlis, Shaji K Kumar, Jeremy A. Ross, P.K. Epling-Burnette

Blood (2022) 140 (Supplement 1): 4242–4244.

https://doi.org/10.1182/blood-2022-160195

Published: 2022

Journal Articles

Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

Ricky Tirtakusuma, Katarzyna Szoltysek, Paul Milne, Vasily V. Grinev, Anetta Ptasinska, Paulynn S. Chin, Claus Meyer, Sirintra Nakjang, Jayne Y. Hehir-Kwa, Daniel Williamson, Pierre Cauchy, Peter Keane, Salam A. Assi, Minoo Ashtiani, Sophie G. Kellaway, Maria R. Imperato, Fotini Vogiatzi, Elizabeth K. Schweighart, Shan Lin, Mark Wunderlich, Janine Stutterheim, Alexander Komkov, Elena Zerkalenkova, Paul Evans, Hesta McNeill, Alex Elder, Natalia Martinez-Soria, Sarah E. Fordham, Yuzhe Shi, Lisa J. Russell, Deepali Pal, Alex Smith, Zoya Kingsbury, Jennifer Becq, Cornelia Eckert, Oskar A. Haas, Peter Carey, Simon Bailey, Roderick Skinner, Natalia Miakova, Matthew Collin, Venetia Bigley, Muzlifah Haniffa, Rolf Marschalek, Christine J. Harrison, Catherine A. Cargo, Denis Schewe, Yulia Olshanskaya, Michael J. Thirman, Peter N. Cockerill, James C. Mulloy, Helen J. Blair, Josef Vormoor, James M. Allan, Constanze Bonifer, Olaf Heidenreich, Simon Bomken

Blood (2022) 140 (17): 1875–1890.

https://doi.org/10.1182/blood.2021015036

Published: 2022

Includes: Supplemental data

NARROW

B-ALL with intrachromosomal amplification of chromosome 21 in a carrier of the Robertsonian translocation rob(14;21)c

Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Lines of Therapy

A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody

The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia

Whole Genome Sequencing for Detection of Prognostically Relevant Genetic Abnormalities in Paediatric Acute Myeloid Leukaemia

Infectious Complications of Bispecific Antibody Therapy in Patients with Multiple Myeloma

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Treatment Outcomes of Childhood Picalm:MLLT10 + Acute Leukemias: An International Retrospective Study

The Efficacy of Same Day Plerixafor Dosing on CD34+ Haematopoietic Stem Cell Collection: A Single Centre Australian Experience

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only